吉林大学学报(医学版) ›› 2023, Vol. 49 ›› Issue (3): 816-822.doi: 10.13481/j.1671-587X.20230335
• 综述 • 上一篇
收稿日期:
2022-06-06
出版日期:
2023-05-28
发布日期:
2023-06-28
通讯作者:
邹颖刚
E-mail:zouyg@jlu.edu.cn
作者简介:
李婧婧(1996-),女,山西省吕梁市人,在读硕士研究生,主要从事妇产科生殖医学方面的研究。
基金资助:
Received:
2022-06-06
Online:
2023-05-28
Published:
2023-06-28
摘要:
卵巢恶性生殖细胞肿瘤(MOGCT)是一种好发于儿童和年轻女性患者的罕见卵巢恶性肿瘤。MOGCT的治疗以手术治疗为主,放化疗为辅,强调综合治疗。传统的根治性手术不仅无法改善患者的预后,还会导致年轻患者永久丧失卵巢内分泌功能和生育能力。随着联合化疗方案的改进,患者预后明显提高,对于有生育需求的年轻患者,只要存在正常卵巢组织,均可保留生育能力,且化疗对卵巢和生殖功能无明显不良影响。妊娠MOGCT患者的治疗原则与非妊娠MOGCT患者相同,但需要在知情选择的基础上综合考虑治疗对母婴的影响并选择合适的治疗方案。目前MOGCT患者保留生育能力方法的有效性及可行性有限。现对MOGCT患者的临床特征、治疗方法及其对生育能力的影响、妊娠与MOGCT的关系、合适生育时机的选择和保留生育能力的方案及选择等方面进行综述,为MOGCT的临床诊疗提供依据。
李婧婧,热孜宛古丽·艾斯凯尔,李丹丹,邹颖刚. 不同治疗方案对卵巢恶性生殖细胞肿瘤患者生育能力影响的研究进展[J]. 吉林大学学报(医学版), 2023, 49(3): 816-822.
1 | DEL-POZO-LÉRIDA S, SALVADOR C, MARTÍNEZ-SOLER F, et al. Preservation of fertility in patients with cancer (Review)[J]. Oncol Rep, 2019, 41(5): 2607-2614. |
2 | 中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 490-500. |
3 | DI TUCCI C, CASORELLI A, MORROCCHI E, et al. Fertility management for malignant ovarian germ cell tumors patients[J]. Crit Rev Oncol Hematol, 2017, 120: 34-42. |
4 | TAMAUCHI S, KAJIYAMA H, YOSHIHARA M, et al. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study[J]. Am J Obstet Gynecol, 2018, 219(4): 385. |
5 | ZHANG N, CHEN R F, HUA K Q,et al. A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors[J].J Ovarian Res,2017,10(1): 52. |
6 | VAN DORP W, HAUPT R, ANDERSON R A, et al. Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer: a review[J]. J Clin Oncol, 2018, 36(21): 2169-2180. |
7 | 中国医师协会妇产科医师分会妇科肿瘤学组. 卵巢恶性肿瘤多学科团队协作诊治的中国专家共识[J]. 中华妇产科杂志, 2021, 56(12): 825-830. |
8 | DE L M R T, PAUTIER P, REY A, et al. Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases[J]. Eur J Cancer, 2011, 47(2): 175-182. |
9 | ZHANG L, CHEN Y, WANG K.Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis[J]. Curr Probl Cancer, 2019, 43(2): 135-144. |
10 | CHOI M C, CHUNG Y S, LEE J W,et al. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R)[J]. Eur J Cancer, 2020, 133: 56-65. |
11 | MIKUŠ M, BENCO N, MATAK L, et al. Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center[J]. Arch Gynecol Obstet, 2020, 301(5): 1227-1233. |
12 | HU T, FANG Y, SUN Q, et al. Clinical management of malignant ovarian germ cell tumors: a 26-year experience in a tertiary care institution[J]. Surg Oncol, 2019, 31: 8-13. |
13 | CEPPI L, GALLI F, LAMANNA M, et al. Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms[J]. Gynecol Oncol, 2019, 152(2): 346-352. |
14 | 韦任姬, 李 力, 张洁清, 等. 影响卵巢恶性生殖细胞肿瘤保留生育功能手术患者预后的因素分析[J]. 肿瘤防治研究, 2014, 41(9): 962-966. |
15 | 刘 倩, 丁西来, 杨佳欣, 等. 卵巢恶性生殖细胞肿瘤手术治疗方式及疗效的多中心临床研究[J]. 中华妇产科杂志, 2013, 48(3): 188-192. |
16 | VASTA F M, DELLINO M, BERGAMINI A, et al. Reproductive outcomes and fertility preservation strategies in women with malignant ovarian germ cell tumors after fertility sparing surgery[J]. Biomedicines, 2020, 8(12): 554. |
17 | RAY-COQUARD I, MORICE P, LORUSSO D,et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(): iv1-iv18. |
18 | LUH L C P N, NYOMAN B M I, AAG P W, et al. Ovarian cancer immature teratoma type in pregnancy: management and feto-maternal outcomes[J]. Open Access Maced J Med Sci, 2019, 7(6): 1016-1020. |
19 | KIM H A, CHOI J, PARK C S, et al. Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery[J]. Endocr Connect, 2018, 7(8): 949-956. |
20 | DELLINO M, SILVESTRIS E, LOIZZI V, et al. Germinal ovarian tumors in reproductive age women: fertility-sparing and outcome[J]. Medicine (Baltimore), 2020, 99(39): e22146. |
21 | NEWTON C, MURALI K, AHMAD A, et al. A multicentre retrospective cohort study of ovarian germ cell tumours: evidence for chemotherapy de-escalation and alignment of paediatric and adult practice[J]. Eur J Cancer, 2019, 113: 19-27. |
22 | APPIAH L C. Fertility preservation for adolescents receiving cancer therapies[J]. Clin Obstet Gynecol, 2020, 63(3): 574-587. |
23 | TURKMEN O, KARALOK A, BASARAN D, et al. Fertility-sparing surgery should be the standard treatment in patients with malignant ovarian germ cell tumors[J]. J Adolesc Young Adult Oncol, 2017, 6(2): 270-276. |
24 | MORRISON A, NASIOUDIS D.Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: a systematic review of the literature[J]. Gynecol Oncol, 2020, 158(2): 476-483. |
25 | ZEMLICKIS D, LISHNER M, DEGENDORFER P, et al. Fetal outcome after in utero exposure to cancer chemotherapy[J]. Arch Intern Med, 1992, 152(3): 573-576. |
26 | BLUMENFELD Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya,oocytes, or ovaries[J].Oncologist,2007,12(9): 1044-1054. |
27 | CHEN Y Y, LUO Y, HAN C, et al. Ovarian dysgerminoma in pregnancy: a case report and literature review[J]. Cancer Biol Ther, 2018, 19(8): 649-658. |
28 | ELBRASHY A A, KAMAL A, FAHIM M I. Methods of treatment and outcome for ovarian germ cell tumors[J]. Indian J Surg Oncol, 2019, 10(4): 640-642. |
29 | SKÖLD C, BJØRGE T, EKBOM A, et al. Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study[J]. Br J Cancer, 2020, 123(1): 161-166. |
30 | KORENAGA T R K, TEWARI K S. Gynecologic cancer in pregnancy[J]. Gynecol Oncol, 2020, 157(3): 799-809. |
31 | BAKRI Y N, EZZAT A, AKHTAR, et al. Malignant germ cell tumors of the ovary. Pregnancy considerations[J]. Eur J Obstet Gynecol Reprod Biol, 2000, 90(1): 87-91. |
32 | FROYMAN W, LANDOLFO C, DE C B, et al. Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study[J].Lancet Oncol, 2019, 20(3): 448-458. |
33 | COCHRANE E, FROST K, DINOBILE C, et al. Immature teratoma diagnosed and treated during pregnancy and later complicated by growing teratoma syndrome: a case review with clinical considerations[J]. Gynecol Oncol Rep, 2020, 32: 100566. |
34 | AMANT F, BERVEILLER P, BOERE I A, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting[J]. Ann Oncol, 2019, 30(10): 1601-1612. |
35 | SHIGEMI D, ASO S, MATSUI H, et al. Safety of laparoscopic surgery for benign diseases during pregnancy: a nationwide retrospective cohort study[J]. J Minim Invasive Gynecol, 2019, 26(3): 501-506. |
36 | YE P P, ZHAO N, SHU J, et al. Laparoscopy versus open surgery for adnexal masses in pregnancy: a meta-analytic review[J]. Arch Gynecol Obstet,2019,299(3): 625-634. |
37 | YOUSSEF R, AHMED G S, ALHYASSAT S, et al. Ovarian dysgerminoma in pregnant women with viable fetus: a rare case report[J]. Case Rep Oncol, 2021, 14(1): 141-146. |
38 | HJORTEBJERG R. IGFBP-4 and PAPP-a in normal physiology and disease[J]. Growth Horm IGF Res, 2018, 41: 7-22. |
39 | ZONG X, YANG J X, ZHANG Y, et al. Clinicopathological characteristics and treatment outcomes of pregnancy complicated by malignant ovarian germ cell tumors[J]. Cancer Manag Res, 2020, 12: 1347-1354. |
40 | LUH L C P N, MAHENDRA I N B, SUWIYOGA K, et al. Management comprehensive multidisciplinary of malignant ovarian germ cell tumors and feto-maternal outcome: a case series report and literature review[J]. Open Access Maced J Med Sci, 2019, 7(7): 1174-1179. |
41 | DE HAAN J, VERHEECKE M, VAN C K, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients[J]. Lancet Oncol, 2018, 19(3): 337-346. |
42 | SON W Y, HENDERSON S, COHEN Y, et al. Immature oocyte for fertility preservation[J]. Front Endocrinol (Lausanne), 2019, 10: 464. |
43 | FISCH B, ABIR R. Female fertility preservation: past, present and future[J]. Reproduction, 2018, 156(1): F11-F27. |
44 | DOLMANS M M, MANAVELLA D D. Recent advances in fertility preservation[J]. J Obstet Gynaecol Res, 2019, 45(2): 266-279. |
45 | DOLMANS M M, DONNEZ J. Fertility preservation in women for medical and social reasons: Oocytes vs ovarian tissue[J]. Best Pract Res Clin Obstet Gynaecol, 2021, 70: 63-80. |
46 | ROUSSET-JABLONSKI C, SELLE F, ADDA-HERZOG E, et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers[J]. Eur J Cancer, 2019, 116: 35-44. |
47 | MASCIANGELO R, BOSISIO C, DONNEZ J, et al. Safety of ovarian tissue transplantation in patients with borderline ovarian tumors[J]. Hum Reprod, 2018, 33(2): 212-219. |
48 | HUSSEIN R S, KHAN Z, ZHAO Y L. Fertility preservation in women: indications and options for therapy[J]. Mayo Clin Proc, 2020, 95(4): 770-783. |
49 | 王秋曼, 赵 烨, 姚丽婷, 等. 接受放化疗年轻女性恶性肿瘤患者的生育能力保存[J]. 国际生殖健康/计划生育杂志, 2019, 38(1): 71-74. |
50 | WANG S S Y, LOONG H, CHUNG J P W, et al. Preservation of fertility in premenopausal patients with breast cancer[J]. Hong Kong Med J, 2020, 26(3): 216-226. |
51 | JOHANSEN G, DAHM-KÄHLER P, STAF C, et al. Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study[J]. Gynecol Oncol, 2019, 155(2): 287-293. |
52 | WEISS A, CHAVEZ-MACGREGOR M, LICHTENSZTAJN D Y, et al. Validation study of the American joint committee on cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer[J]. JAMA Oncol, 2018, 4(2): 203-209. |
53 | LAMBERTINI M, CINQUINI M, MOSCHETTI I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology[J]. Eur J Cancer, 2017, 71: 25-33. |
54 | 丁海遐, 李 文. 女性生育力保存国际指南解读[J]. 实用妇产科杂志, 2020, 36(5): 354-357. |
55 | CHO E, KIM Y Y, NOH K, et al. A new possibility in fertility preservation: the artificial ovary[J]. J Tissue Eng Regen Med, 2019, 13(8): 1294-1315. |
56 | LARONDA M M, RUTZ A L, XIAO S, et al. A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice[J]. Nat Commun, 2017, 8: 15261. |
[1] | 马园,杨帅,王瑶琪,孟宪瑛. 分化型甲状腺癌患者妊娠期间激素水平变化及其对疾病发生发展影响的研究进展[J]. 吉林大学学报(医学版), 2023, 49(3): 811-815. |
[2] | 杨仁义,彭书旺,王永恒,董宇轩,段姗姗. 甲状腺癌铁死亡预后风险模型的构建及其潜在机制的生物信息学分析[J]. 吉林大学学报(医学版), 2023, 49(2): 402-413. |
[3] | 王小燕,胡溢洪,韩语诚,邹先琼. COMMD7在脑低级别胶质瘤发生发展中作用机制的生物信息学分析[J]. 吉林大学学报(医学版), 2023, 49(2): 414-424. |
[4] | 叶雅萍,范岩峰,丁露,王龙梅,李萍. 不同血清抗苗勒管激素水平对多囊卵巢综合征患者助孕结局的影响[J]. 吉林大学学报(医学版), 2023, 49(2): 501-507. |
[5] | 翁丹,段海霞. 基于多个影响因素建立列线图模型预测IVF-ET患者发生异位妊娠的风险[J]. 吉林大学学报(医学版), 2023, 49(1): 158-165. |
[6] | 白杨,杨晨曦,刘小强,刘羽,邢倩. 系统性红斑狼疮患者妊娠期外周血中滤泡辅助性T淋巴细胞的变化及其意义[J]. 吉林大学学报(医学版), 2023, 49(1): 166-172. |
[7] | 高云鹤,姚佳楠,曹岚清,许传杰. 不同部位孤立性纤维性肿瘤患者临床病理特征和预后影响因素分析[J]. 吉林大学学报(医学版), 2022, 48(6): 1510-1517. |
[8] | 侯俊杰,米旭光,李孝男,李晓男,杨影,芦小单,方艳秋,金宁一. 基于乳酸代谢基因的肺腺癌预后模型的建立和评价[J]. 吉林大学学报(医学版), 2022, 48(6): 1546-1554. |
[9] | 高红,林莉,颜晓红,陶萍,李友筑. 促性腺激素释放激素拮抗剂灵活方案中促黄体生成素一过性早升对新鲜周期IVF/ICSI-ET患者妊娠结局的影响[J]. 吉林大学学报(医学版), 2022, 48(6): 1566-1573. |
[10] | 沈珂羽,付晶瑶,肖思齐,吴宪吉,张广. 低危甲状腺微小乳头状癌术前评估与预后相关因素的研究进展[J]. 吉林大学学报(医学版), 2022, 48(6): 1650-1656. |
[11] | 高红,颜晓红,林莉,任璐璐,李友筑. 辅助生殖技术助孕妊娠后患者晚期自然流产危险因素分析[J]. 吉林大学学报(医学版), 2022, 48(5): 1298-1304. |
[12] | 刘莎莎,赵云,孙国强,陈菲菲. 妊娠期糖尿病患者胎盘组织中Apelin和APJ的表达及其对滋养层细胞胰岛素抵抗和行为的影响[J]. 吉林大学学报(医学版), 2022, 48(5): 1314-1323. |
[13] | 胡连涛,邓文俊,鹿士振,孙跞,李学斌,黎楚豪,王欣然,张春斌,李玥,王伟群. CC趋化因子配体20在肝细胞癌组织中的表达及其在肝细胞肝癌预后评估中作用的生物信息学分析[J]. 吉林大学学报(医学版), 2022, 48(4): 1010-1017. |
[14] | 牛英杰,查勇,李思嘉,王青,唐诗聪,李红阳. 胆管癌根治性切除术后患者预后相关因素分析和生存预测模型构建[J]. 吉林大学学报(医学版), 2022, 48(4): 979-987. |
[15] | 从相国,陈欣欣,吴英,曹梦蝶,李淑湘,陈蕾,沈琼. 妊娠早期孕妇血清碘和铁水平与甲状腺功能及甲状腺自身抗体的关系[J]. 吉林大学学报(医学版), 2022, 48(4): 988-994. |
|